The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | The treatment of young and fit, older and fit, and frail patients with multiple myeloma in Ireland
Denis O’Keeffe, MD, University Hospital Limerick, Limerick, Ireland, gives an overview of the treatment options available for patients with multiple myeloma in Ireland, highlighting some of the toxicities associated with these therapies. Whilst young and fit patients can be treated with a combination of lenalidomide, bortezomib, and dexamethasone, or with daratumumab, bortezomib, thalidomide, and dexamethasone, older and fit patients who cannot undergo transplantation will be treated with lenalidomide, bortezomib, and lower dose dexamethasone. Frail patients can be treated with bortezomib and lenalidomide or melphalan with steroids depending on their frailty level. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
